CSL Full Year Statutory Accounts for the Year Ended 30/06/19
Filed with ASX · · 106 pages · English
Lodged with the ASX under Listing Rule 4.3A. Contents Results for Announcement to the Market Additional Information Financial Report Appendix 4E Full-year Ended 30 June 2019 (Previous corresponding period: Year ended 30 June 2018) Results for Announcement to the Market Reported • Sales revenue up 8.1% to US$8.2 billion. • Net profit after tax for the year attributable to members of the parent enti
Earlier from CSL
- Update on CSL transition to own distributor model in China
- Half Year Results Analyst Presentation
- Appendix 4D and Half Year Accounts
- CSL R&D Investor Briefing
- Full Year Results Announcement
Later from CSL
- Research and Development Investor Briefing 2019
- CSL Statutory Accounts for the Half Year Ended 31/12/2019
- New Debt Facilities to Strengthen Maturity Profile
- Change in Leadership of CSLs Finance Function
- CSL to acquire LateStage Gene Therapy Candidate from uniQure
Follow CSL into a list and get an email when it puts out news.
Follow CSL